Highlights from ELCC Day 1

Eric K. Singhi:

“Amivantamab’s biggest challenge has been its toxicity—the degree of OS benefit won’t translate in the real world without supportive measures. Kudos to the sponsor for investing in these (IMO) practice-changing supportive measures.”

Jarushka Naidoo:

“Ph I Daraxonrasib (RAS-On panRAS inhibitor) in RAS+ NSCLC: – ORR 38% – mPFS 9.8m, mDOR 15.1m – modest tox (diarrhea and rash) – 200mg dose selected for ph III Promising. Delighted Ph III RASolve trial of this agent, coming to Ireland.”

Lung Cancer Europe:

“We’re in Paris for the European Lung Cancer Congress 2025.

Anne-Marie Baird, our President, Alexandre Brutti, our Treasurer, and Tihany Carrillo, Ops Coordinator, are eager to discuss advancements and collaboration opportunities in lung cancer care.

ELCC serves as an essential platform for exchanging valuable insights and fostering connections within the lung cancer community.

We’re at booth 484 and are looking forward to engaging about the latest in lung cancer treatment, advocacy, and patient support.

Please drop by to connect with us, share your insights, or learn more about our initiatives.”

Narjust Florez:

“Truly love this slide by Dr. Saw when discussing 3 abstracts from todays session – it is never a black and white scenario for our patients and many aspects need to be taken into account.”

Giannis Mountzios:

“Ben Creelan takes us to an exciting journey on cellular therapies for solid tumors with a focus on CAR T cells for lung cancer. A plethora of neoantogens to exploit as a target ( also in squamous! ) to generate durable immune responses.”

Julien Mazieres:

“The most awaited slide of the ELCC25 OS from the MARIPOSA trial. Clearly positive trial reinforcing the interest of Amivantamab + Lazertinib in 1L for EGFR At what cost ? dermatologic tox, VTEs, infusion reaction… High-maintenance treatment !”

Jarushka Naidoo:

“ELCC25 Mini Orals

Ph II KROCUS trial: 1L fulzerasib + cetuximab in KRAS G12C+ NSCLC by Marga Majem

– ORR 68.9% (by investigator 80%)
– DCR 100%
– mPFS 12.5m
– very tolerable tox, activity in STK11+, KEAP1+.”

ESMO:

“ELCC25: 2025 Heine H. Hansen Award recipient, Keith Kerr, explains how Lung Cancer pathology has evolved over the years and discusses priorities for the future.”

Jill Feldman:

“I have many thoughts (surprise ), but ultimately, there isn’t a one-size-fits-all treatment. It’s unsettling that opinions are being formed already based on side effects without seeing the COCOON data that will be presented today. I am a passionate and vocal advocate for QOL, but we can’t ignore the survival data. This isn’t about gaining a few extra months’ – 12+ months is significant and should not be overlooked!

I can’t help but think personally about:

1. My dad would have lived to see me graduate 8th grade (he died a few weeks before), maybe even high school.

2. My mom would have lived to see the birth of my daughter (she died 6 months before) and likely all of my children. That MATTERS, too! While I can’t say what my parents would have chosen, I it is ultimately the patient’s/family’s choice! Every family deserves the information and opportunity to discuss ALL options (Informed decision-making).

This respect for patient choice should be a priority. I also feel strongly that the COCOON data should have been presented alongside the MARIPOSA data. It’s just as crucial (even more) because it addresses the significant barrier of side effects that impact whether a patient can stay on treatment. Kudos to J&J for listening to what’s important to patients and developing a study to address the side effects up front!

If QOL truly matters, then so should the data that addresses it! Presenting them together tells a much bigger story and would have changed the conversation. I implore researchers, clinicians, and conference organizers to think about this going forward.”

Benjamin Besse:

“Debate on L1 for EGFR mut NSCLC : ‘easy osi’ then escalate to CT-ami, or use doublet upfront? Lazertinib+amivantmab likely to extend OS by ~ 1 yr vs osimertinib, but without cross over to CT-ami. Intensify only if ctEGFR not cleared after 4w of osi?”

Raffaele Giusti:

“MARIPOSA OS data at ELCC25 While the combination offers a statistically significant OS advantage, the absolute clinical benefit is disappointingly modest.

Should more always mean better? Or should we be striving for smarter, not just stronger, strategies?”

Julien Mazieres:

“Another brick in the wall of HER2 mut NSCLC. Promising efficacy of BAY in HER2 naive pts (ORR 70.5%) but also in patients treated with TDxD (ORR 35.3%). Diarrhea as the most frequent AE (almost all pts but no tt discontinuation). ”

Read OncoDaily’s summary of MARIPOSA trial.